Research location
Port Jefferson Station
New York, United States
Advertisement
Research activity in Port Jefferson Station
New York, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 36 trials and 43 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Port Jefferson Station
36 linked trials · page 1 of 1Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorNCT06472245 · 2024-12-03 · 2 site observations
RECRUITING
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.NCT06072612 · 2023-12-05 · 3 site observations
RECRUITING
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956 · 2023-11-17 · 1 site observation
RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)NCT06126224 · 2023-08-28 · 1 site observation
RECRUITING
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionNCT05245500 · 2022-06-09 · 2 site observations
RECRUITING
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast CancerNCT05304962 · 2022-03-04 · 1 site observation
RECRUITING
A Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632 · 2020-06-08 · 1 site observation
RECRUITING
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06683508 · 2024-11-13 · 1 site observation
COMPLETED
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT06603571 · 2024-09-20 · 1 site observation
COMPLETED
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06230523 · 2024-02-05 · 1 site observation
COMPLETED
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06124807 · 2023-11-17 · 1 site observation
COMPLETED
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 · 2023-11-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)NCT05555732 · 2023-01-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationNCT05609578 · 2022-11-22 · 2 site observations
ACTIVE_NOT_RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382286 · 2022-07-25 · 2 site observations
ACTIVE_NOT_RECRUITING
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382299 · 2022-07-20 · 2 site observations
ACTIVE_NOT_RECRUITING
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung CancerNCT05014815 · 2021-11-16 · 1 site observation
COMPLETED
Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology TreatmentNCT04862195 · 2021-05-15 · 1 site observation
TERMINATED
Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation ToxicityNCT04580667 · 2020-10-01 · 1 site observation
WITHDRAWN
Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's PatientsNCT04524351 · 2020-08-14 · 1 site observation
COMPLETED
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerNCT04100018 · 2020-02-06 · 1 site observation
COMPLETED
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR GenesNCT04171700 · 2020-01-16 · 1 site observation
TERMINATED
Prospective Clinicogenomic ProgramNCT04180176 · 2019-12-13 · 1 site observation
COMPLETED
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC PatientsNCT03569280 · 2019-11-26 · 1 site observation
COMPLETED
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerNCT03906071 · 2019-07-15 · 1 site observation
TERMINATED
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)NCT03976375 · 2019-06-26 · 1 site observation
COMPLETED
Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic CancerNCT03892096 · 2019-03-01 · 1 site observation
COMPLETED
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationNCT03318939 · 2017-10-11 · 1 site observation
TERMINATED
Palbociclib in Real World PracticeNCT03280303 · 2017-01-04 · 1 site observation
COMPLETED
Evaluation of a Medical Food for Chronic WoundsNCT00711217 · 2008-06-01 · 1 site observation
COMPLETED
Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot UlcersNCT00318214 · 2006-06-01 · 1 site observation
TERMINATED
Safety and Efficacy Study of MRE0094 to Treat Chronic, Neuropathic, Diabetic Foot UlcersNCT00312364 · 2005-12-01 · 1 site observation
COMPLETED
Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid ArthritisNCT00049751 · 2002-09-01 · 1 site observation
COMPLETED
Long Term Open Label Continuation StudyNCT00195650 · 2000-07-01 · 1 site observation
COMPLETED
Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 PositiveNCT03178071 · 1 site observation
NO_LONGER_AVAILABLE
A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic PainNCT00002160 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.